Active substance
Results for the substance atazanavir+cobicistat
1 result
About this active substance
The combination of atazanavir and cobicistat is used for the treatment of human immunodeficiency virus (HIV) infection. Atazanavir is a protease inhibitor that reduces HIV replication, while cobicistat is a pharmacokinetic enhancer that increases plasma concentrations of atazanavir, prolonging its effect.
This combination is administered orally, usually once daily, with food to improve absorption. It is used as part of highly active antiretroviral therapy (HAART) and is indicated for adult and adolescent patients aged 12 years and older.
Common side effects include nausea, jaundice, headaches, fatigue, and skin rashes. In rare cases, severe adverse reactions such as liver impairment, renal failure, or allergic reactions may occur.
Patients taking this combination should undergo regular monitoring for liver and kidney function and bilirubin levels. Additionally, the medication may interact with other treatments, requiring caution. The atazanavir and cobicistat combination provides an effective option for managing HIV infection, helping to reduce viral load and improve patients' quality of life.
This combination is administered orally, usually once daily, with food to improve absorption. It is used as part of highly active antiretroviral therapy (HAART) and is indicated for adult and adolescent patients aged 12 years and older.
Common side effects include nausea, jaundice, headaches, fatigue, and skin rashes. In rare cases, severe adverse reactions such as liver impairment, renal failure, or allergic reactions may occur.
Patients taking this combination should undergo regular monitoring for liver and kidney function and bilirubin levels. Additionally, the medication may interact with other treatments, requiring caution. The atazanavir and cobicistat combination provides an effective option for managing HIV infection, helping to reduce viral load and improve patients' quality of life.